ライフサイエンスコーパス: 3,4-dihydroxyphenylalanine

1 or aryloxy radical coupling to form di-DOPA (3,4-dihydroxyphenylalanine).

2 -stimulating hormone, 8-methoxypsoralen, and 3,4-dihydroxyphenylalanine).

3 nt motor deficits that can be rescued with L-3,4 dihydroxyphenylalanine.

4 of PD and following the treatment of drug l-3,4-dihydroxyphenylalanine.

5 inst tyrosine and to a lesser extent against 3,4-dihydroxyphenylalanine.

6 bacterial phospho-tyrosines to protein-bound 3,4-dihydroxyphenylalanine.

7 d were not related to melanin formation from 3,4-dihydroxyphenylalanine.

8 stinctly unusual ones, 6-bromotryptophan and 3,4-dihydroxyphenylalanine.

9 6-(18)F-fluoro-l-3,4-dihydroxyphenylalanine ((18)F-DOPA) PET is a useful

10 ibution, and prognostic value of fused (18)F-3,4-dihydroxyphenylalanine ((18)F-DOPA) PET/MR images in

11 )I-metaiodobenzylguanidine, 6-(18)F-fluoro-l-3,4-dihydroxyphenylalanine, (18)F-FDG, and (68)Ga-DOTA-s

12 ination of protein-bound 3-nitrotyrosine and 3, 4-dihydroxyphenylalanine (3-hydroxytyrosine) as speci

13 It was able to block the L-3,4-dihydroxyphenylalanine accumulation produced by CI-1

14 mino)methyl]chromen-2-one, increased DOPA (L-3,4-dihydroxyphenylalanine) accumulation 51% in the hipp

15 The incorporation of the amino acid DOPA (3,4-dihydroxyphenylalanine) allows the self-assembled na

16 Finally, we revealed that the synthesis of L-3,4-dihydroxyphenylalanine, an important metabolite of L

17 demonstrated by rescue of the dysfunction by 3, 4-dihydroxyphenylalanine and considerable dopaminergi

18 L-3,4-dihydroxyphenylalanine and reserpine have been used

19 icroscopy have been used to determine that l-3,4-dihydroxyphenylalanine and reserpine increase and de

20 rs (alpha-melanocyte-stimulating hormone and 3,4-dihydroxyphenylalanine) and inhibitors (hydroquinone

21 abundance and proximity of catecholic Dopa (3,4-dihydroxyphenylalanine) and lysine residues hint at

22 e precursor and Parkinson's therapy agent, L-3,4-dihydroxyphenylalanine, and at cell clusters incubat

23 Dopamine (DA), its precursor 3,4-dihydroxyphenylalanine, and metabolite 3,4-dihydroxy

24 as: Trp > norleucine > Phe, Leu > Ile > His >3,4-dihydroxyphenylalanine, Arg > Val > Lys, Tyr, Pro >

25 reatment with a norepinephrine precursors (l-3,4-dihydroxyphenylalanine at 100 mg/kg or l-threo-dihyd

26 ich catalyzes the oxidation of serotonin and 3,4-dihydroxyphenylalanine by H(2)O(2).

27 anogenic enzymes include Tyrp1 (or TRP1) and 3,4-dihydroxyphenylalanine-chrome tautomerase (Dct or TR

28 have utilized monoamine oxidase (MAO) and L-3,4-dihydroxyphenylalanine decarboxylase (DDC) for micro

29 Aspartate 1-decarboxylase (ADC) and 3,4-dihydroxyphenylalanine decarboxylase (DDC) provide b

30 des a new member of the opium poppy tyrosine/3,4-dihydroxyphenylalanine decarboxylase gene family (Ty

31 ive identity with other opium poppy tyrosine/3,4-dihydroxyphenylalanine decarboxylases (84%), and whe

32 These results support the use of L-3, 4-dihydroxyphenylalanine derivatives of PEI in any at

33 3, 4-Dihydroxyphenylalanine (Dopa) residues in Mfps medi

34 The high content of 3,4-dihydroxyphenylalanine (Dopa) (~30 mol %) and its lo

35 g), a 5-HT(1A) receptor agonist, decreased l-3,4-dihydroxyphenylalanine (DOPA) accumulation in rat st

36 developed for enantiomeric quantification of 3,4-dihydroxyphenylalanine (DOPA) and its precursors, ph

37 s to achieve enantioselective recognition of 3,4-dihydroxyphenylalanine (DOPA) based on a new mechani

38 ter cuticle of byssal threads given its high 3,4-dihydroxyphenylalanine (Dopa) content at 10-15 mol %

39 Concomitantly, GBL treatment [along with the 3,4-dihydroxyphenylalanine (dopa) decarboxylase inhibito

40 easuring dopamine synthesis (accumulation of 3,4-dihydroxyphenylalanine (DOPA) following decarboxylas

41 p(1) residue of alpha-factor was replaced by 3,4-dihydroxyphenylalanine (DOPA) for periodate-mediated

42 xylbetaine) (pCB) and four surface-binding l-3,4-dihydroxyphenylalanine (DOPA) groups, pCB-(DOPA)4, w

43 The interaction between a 3,4-dihydroxyphenylalanine (DOPA) labeled analogue of th

44 in chemically defined minimal medium with L-3,4-dihydroxyphenylalanine (DOPA) or (-)-epinephrine pro

45 was to evaluate the diagnostic role of (18)F-3,4-dihydroxyphenylalanine (DOPA) PET/CT at the time of

46 AS) catalyzes oxygen-dependent conversion of 3,4-dihydroxyphenylalanine (dopa) to 3,4-dihydroxyphenyl

47 lated nonenzymatically to the DA precursor l-3,4-dihydroxyphenylalanine (DOPA) under pro-oxidant cond

48 mic the cross-linking of proteins containing 3,4-dihydroxyphenylalanine (DOPA) used by shellfish for

49 aining sequences in polypeptides to peptidyl 3,4-dihydroxyphenylalanine (DOPA) using mushroom tyrosin

50 egy exploits the adhesive characteristics of 3,4-dihydroxyphenylalanine (DOPA), an important componen

51 inactive against tyrosine, phenylalanine and 3,4-dihydroxyphenylalanine (dopa), tdc1 was developmenta

52 (A. pectinata foot protein-1, apfp-1) with L-3,4-dihydroxyphenylalanine (DOPA)-containing and mannose

53 As the first of the 3,4-dihydroxyphenylalanine (Dopa)-containing byssal prec

54 We found that only l-3,4-dihydroxyphenylalanine (DOPA)-containing peptides we

55 We previously reported l-3,4-dihydroxyphenylalanine (dopa)-histidine (dopa-His) a

56 ilable animal models of PD fail to display l-3,4-dihydroxyphenylalanine (DOPA)-responsive parkinsonis

57 is expressed by the selective recognition of 3,4-dihydroxyphenylalanine (DOPA).

58 ine, trans-2,3-cis-3,4-dihydroxyproline, and 3,4-dihydroxyphenylalanine (Dopa).

59 ulfotransferase (PST), SULT1A3, has a unique 3,4-dihydroxyphenylalanine (Dopa)/tyrosine-sulfating act

60 synergy between flanking lysine (Lys, K) and 3,4-Dihydroxyphenylalanine (DOPA, Y) residues in the mus

61 levels of dopamine (DA) and its metabolites, 3,4-dihydroxyphenylalanine (DOPAC) and homovanillic acid

62 ic amines significant to the fly including L-3,4-dihydroxyphenylalanine, dopamine, tyramine, and sero

63 ehaviorally effective dose of DA precursor l-3,4-dihydroxyphenylalanine effectively reversed these ch

64 ically relevant cargos, nipecotic acid and l-3,4-dihydroxyphenylalanine (i.e., l-DOPA), were attached

65 alyzes the hydroxylation of tyrosine to form 3,4-dihydroxyphenylalanine in the biosynthesis of the ca

66 Dopa (3,4-dihydroxyphenylalanine) is recognized as a key chemi

67 represents decarboxy-(E)-alpha,beta-dehydro-3,4-dihydroxyphenylalanine, is a potently antimicrobial

68 ptophan, R(**) is dihydroxyarginine, Y(*) is 3,4-dihydroxyphenylalanine, K(*) is 5-hydroxylysine, and

69 In the present investigation, L-3, 4-dihydroxyphenylalanine (L-DOPA) was conjugated on H

70 dopamine receptor agonists apomorphine and L-3, 4-dihydroxyphenylalanine (L-DOPA).

71 Here, we explore the evolution of l-3,4-dihydroxyphenylalanine (l-DOPA) 4,5-dioxygenase (DOD

72 tivity in dopamine-deficient mice than did l-3,4-dihydroxyphenylalanine (l-dopa) administration, whic

73 tivity of one variant could be improved by l-3,4-dihydroxyphenylalanine (l-DOPA) administration; this

74 l-binding non-canonical amino acids (NCAAs), 3,4-dihydroxyphenylalanine (L-DOPA) and (8-hydroxyquinol

75 escribe a simple one-pot method, employing l-3,4-dihydroxyphenylalanine (L-DOPA) as a reducing/cappin

76 The catechol group of 3,4-dihydroxyphenylalanine (L-DOPA) derived from L-tyros

77 Treatment of Parkinson disease (PD) with L-3,4-dihydroxyphenylalanine (L-DOPA) dramatically relieve

78 DA-/-) mice required daily administration of 3,4-dihydroxyphenylalanine (L-DOPA) for survival beyond

79 The application of L-3,4-dihydroxyphenylalanine (L-DOPA) increased the IPSC i

80 The dopamine precursor L-beta-3,4-dihydroxyphenylalanine (L-DOPA) inhibited cleavage o

81 th saline; a synthetic dopamine precursor, L-3,4-dihydroxyphenylalanine (L-DOPA) methyl ester; a dire

82 electropolymerization of dopamine (DA) and L-3,4-dihydroxyphenylalanine (L-DOPA) on carbon nano-onion

83 nist SKF 82958 and the indirect DA agonist L-3,4-dihydroxyphenylalanine (L-DOPA) on the acoustic star

84 was tested in 7 aged rhesus monkeys using L-3,4-dihydroxyphenylalanine (L-dopa) or the selective dop

85 Although L-3,4-dihydroxyphenylalanine (L-DOPA) remains the referenc

86 he loss of midbrain dopaminergic neurons and 3,4-dihydroxyphenylalanine (L-DOPA) reversible behaviora

87 Ever since its introduction 40 years ago l-3,4-dihydroxyphenylalanine (l-DOPA) therapy has retained

88 ent of dyskinesia that result from chronic L-3,4-dihydroxyphenylalanine (L-DOPA) therapy.

89 Daily treatment of DD mice with L-3,4-dihydroxyphenylalanine (L-DOPA) transiently restores

90 athophysiology and dyskinesia from chronic L-3,4-dihydroxyphenylalanine (L-DOPA) treatment, but the p

91 to dopamine D1 or D2 receptor agonists and l-3,4-dihydroxyphenylalanine (l-DOPA) was 3- to 13-fold gr

92 aring" clinical practice that avoids using L-3,4-dihydroxyphenylalanine (L-DOPA), a dopamine precurso

93 L-3,4-dihydroxyphenylalanine (L-DOPA), a naturally occurri

94 can be achieved by daily administration of L-3,4-dihydroxyphenylalanine (L-dopa), a precursor of dopa

95 y treated with the dopamine (DA) precursor l-3,4-dihydroxyphenylalanine (L-DOPA), but its prolonged u

96 anging freely, and injected with 100 mg/kg l-3,4-dihydroxyphenylalanine (L-DOPA), engage in a behavio

97 dministration of the antiparkinsonian drug l-3,4-dihydroxyphenylalanine (l-DOPA), is accompanied by a

98 ve significantly less amounts of dopamine, l-3,4-dihydroxyphenylalanine (L-DOPA), salsolinol, and N-a

99 L-3,4-Dihydroxyphenylalanine (L-DOPA), synthesized from L-

100 BST) as a structure putatively involved in L-3,4-dihydroxyphenylalanine (L-Dopa)-induced dyskinesia (

101 rch of brain nuclei putatively involved in L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (

102 Furthermore, in a mouse model of L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (

103 is disrupted in Parkinson's disease and in l-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesia (

104 antagonists have targeted PD patients with L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (

105 developed treatment complications known as L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (

106 L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia i

107 ly the 3-hydroxylation of tyrosine to form l-3,4-dihydroxyphenylalanine (l-DOPA).

108 4-dihydroxyphenylacetaldehyde (DHPAA) from L-3,4-dihydroxyphenylalanine (L-DOPA).

109 can be maintained by daily treatment with l-3,4-dihydroxyphenylalanine (L-dopa).

110 can be synthesized by another pathway via l-3,4-dihydroxyphenylalanine (L-DOPA).

111 on unless the animals were pretreated with l-3,4-dihydroxyphenylalanine (l-dopa).

112 administration of the dopamine precursor, L-3,4-dihydroxyphenylalanine (L-dopa).

113 lls incubated with the dopamine precursor, L-3,4-dihydroxyphenylalanine (L-DOPA).

114 They are rescued by daily treatment with L-3,4-dihydroxyphenylalanine (L-DOPA); each dose restores

115 pamine is restored by daily treatment with l-3-4-dihydroxyphenylalanine (l-dopa).

116 CFA receptors GPR43/GPR109A, and modulated L-3,4-dihydroxyphenylalanine levels and the abundance of T

117 l-3,4-dihydroxyphenylalanine-mediated dyskinesias were als

118 Dopamine- and 3,4-dihydroxyphenylalanine-melanin products were identif

119 Ultraviolet-Vis absorbance spectra of L-3,4-dihydroxyphenylalanine-melanin solutions at differen

120 o produce dioxindolyl-L-alanine, kynurenine, 3,4-dihydroxyphenylalanine, N'-formylkynurenine, and 5-h

121 Analytes including L-3,4-dihydroxyphenylalanine, N-acetyl octopamine, N-acety

122 slation remains largely limited to the Dopa (3,4-dihydroxyphenylalanine) or catechol functionality, w

123 aling using the dopamine precursor l-DOPA (l-3,4-dihydroxyphenylalanine) or dopamine receptor agonist

124 In cultured human RPE, KL increases the l-3,4-dihydroxyphenylalanine synthesis and inhibits vascul

125 omeno[3,4-c]pyridin-5-one, increased DOPA (L-3,4-dihydroxyphenylalanine) synthesis 84% in the hippoca

126 L-3,4-dihydroxyphenylalanine, the immediate precursor of d

127 tor behaviors (dyskinesias) in response to l-3,4-dihydroxyphenylalanine, the principal treatment for

128 nephrine, norepinephrine, octopamine (OA), L-3, 4-dihydroxyphenylalanine, tyramine (TA), and serotoni